3-butyl-5,6-diaminouracil | 81250-31-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-butyl-5,6-diaminouracil
• 英文别名: 5,6-diamino-3-butyl-1,3-dihydropyrimidine-2,4-dione；5,6-diamino-3-butyl-1H-pyrimidine-2,4-dione
• CAS: 81250-31-9
• 化学式: C₈H₁₄N₄O₂
• 分子量: 198.225
• InChiKey: USWCRMBFRFQYQI-UHFFFAOYSA-N

物化性质

• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-butyl-5,6-diaminouracil 在 氯化亚砜 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione
  参考文献：
  名称：

  1,8-Disubstituted Xanthine Derivatives:  Synthesis of Potent A_2B-Selective Adenosine Receptor Antagonists

  摘要：

  3-Unsubstituted xanthine derivatives bearing a cyclopentyl or a phenyl residue in the 8-position were synthesized and developed as A(2)B adenosine receptor antagonists. Compounds bearing polar substituents were prepared to obtain water-soluble derivatives. 1-Alkyl-8-phenylxanthine derivatives were found to exhibit high affinity for A(2B) adenosine receptors (ARs). 1,8-Disubstituted xanthine derivatives were equipotent to or more potent than 1,3,8-trisubstituted xanthines at A(2B) ARs, but generally less potent at A(1) and A(2A), and much less potent at A(3) ARs. Thus, the new compounds exhibited increased A2B selectivity versus all other AR subtypes. 9-Deazaxanthines (pyrrolo[2,3-d]pyrimidindiones) appeared to be less potent at A(2B) ARs than the corresponding xanthine derivatives. 1-Propyl-8-p-sulfophenylxanthiiie (17) was the most selective compound of the present series, exhibiting a K-i value of 53 nM at human A(2B) ARs and showing greater than 180-fold selectivity versus human A, ARs. Compound 17 was also highly selective versus rat A, ARs (41-fold) and versus the other human AR subtypes (A(2A) > 400-fold and A3 > 180-fold). The compound is highly water-soluble due to its sulfonate function. 1-Butyl-8-p-carboxyphenylxanthine (10), another polar analogue bearing a carboxylate function, exhibited a K-i value of 24 nM for A(2B) ARs, 49-fold selectivity versus human and 20-fold selectivity versus rat A, ARs, and greater than 150-fold selectivity versus human A2A and A3 ARs. 8-[4-(2-Hydroxyethylamino)-2-oxoethoxy)phenyl]-1-propylxanthine (29) and 1-butyl-8-[4(4-benzyl)piperazino-2-oxoethoxy)phenyl]xanthine (35) were among the most potent A(2B) antagonists showing K-i values at A(2B) ARs of 1 nM, 57-fold (29) and 94-fold (35) selectivity versus human A(1), ca. 30-fold selectivity versus rat A(1), and greater than 400-fold selectivity versus human A(2A) and A(3) ARs. The new potent, selective, water-soluble A(2B) antagonists may be useful research tools for investigating A(2B) receptor function.

  DOI：

  10.1021/jm011049y
• 作为产物：
  描述：

  5-nitroso-6-amino-3-butyl-1,3-dihydropyrimidine-2,4-dione 在 氨 、 sodium hydrogensulfite 作用下， 以 水 为溶剂， 生成 3-butyl-5,6-diaminouracil
  参考文献：
  名称：

  [EN] XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS
  [FR] DERIVES DE XANTHINE SERVANT D'ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE A2B

  摘要：

  揭示了一种A2B腺苷受体拮抗剂化合物，可用于治疗包括哮喘和腹泻在内的各种疾病状态。

  公开号：

  WO2004106337A1

文献信息

• Preparation, Properties, Reactions, and Adenosine Receptor Affinities of Sulfophenylxanthine Nitrophenyl Esters:  Toward the Development of Sulfonic Acid Prodrugs with Peroral Bioavailability
  作者：Luo Yan、Christa E. Müller

  DOI：10.1021/jm0310030

  日期：2004.2.1

  esters of p-sulfophenylxanthine derivatives were synthesized as model compounds. The target xanthine derivatives were obtained in high yields by condensation of the appropriate 5,6-diaminouracils with 4-(nitrophenoxysulfonyl)benzoic acids in the presence of a carbodiimide, followed by ring closure with polyphosphoric acid trimethylsilyl ester. The chemical and enzymatic stability of the m-nitrophenyl

  P2嘌呤能受体的许多目前已知的拮抗剂是带有一个或几个苯基磺酸酯基的阴离子分子。在P1（腺苷）受体拮抗剂中，黄嘌呤苯磺酸盐是一类有效的化合物。由于它们的高酸度，苯磺酸盐在生理pH值下带负电荷，并且不易穿透细胞膜。本研究旨在通过将磺酸盐转化为化学稳定的硝基苯基酯来开发其亲脂性，口服可生物利用的前药。使用甲苯磺酸硝基苯酯作为模型化合物在不同pH值下进行的初始稳定性测试表明，间硝基苯酯在很宽的pH范围内都是稳定的，而邻位和对位异构体在强酸性或碱性条件下则较不稳定。合成了对磺基苯基黄嘌呤衍生物的一系列间硝基和对硝基苯基酯作为模型化合物。通过在碳二亚胺存在下将合适的5,6-二氨基尿嘧啶与4-（硝基苯氧基磺酰基）苯甲酸缩合，然后用多磷酸三甲基甲硅烷基酯闭环，以高收率获得目标黄嘌呤衍生物。通过毛细管电泳在体外研究了间硝基苯酯的化学和酶稳定性。观察到在水溶液，人造胃酸和血清中的高稳定性。但是，用作原型黄嘌呤
• A2B adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050101778A1

  公开（公告）日：2005-05-12

  Disclosed are novel A 2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

  揭示了具有Formula I或Formula II结构的新型A2B腺苷受体拮抗剂：这些化合物特别适用于治疗哮喘、炎症性胃肠道疾病、心血管疾病、神经系统疾病以及与不良血管生成相关的疾病。
• A2B Adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050261316A1

  公开（公告）日：2005-11-24

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  揭示了一种新颖的化合物，它们是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。
• A2B ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Kalla Rao

  公开号：US20080318983A1

  公开（公告）日：2008-12-25

  Disclosed are methods for treating asthma, inflammatory gastrointestinal tract disorders, cancer, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis using A 2B adenosine receptor antagonists having the structure of Formula I or Formula II:

  本发明涉及使用具有结构公式I或公式II的A2B腺苷受体拮抗剂治疗哮喘、炎症性肠道疾病、癌症、心血管疾病、神经系统疾病和与不良血管生成有关的疾病的方法。
• A2B Adenosine Receptor Antagonists
  申请人：Kalla Rao

  公开号：US20100222300A1

  公开（公告）日：2010-09-02

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  本发明揭示了一类新的化合物，它们是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。